These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25691720)

  • 1. Industry perspective on the medical risk of visible particles in injectable drug products.
    Bukofzer S; Ayres J; Chavez A; Devera M; Miller J; Ross D; Shabushnig J; Vargo S; Watson H; Watson R
    PDA J Pharm Sci Technol; 2015; 69(1):123-39. PubMed ID: 25691720
    [No Abstract]   [Full Text] [Related]  

  • 2. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aseptic process monitoring--a better strategy. Validation Group, Inc.
    Wilson JD
    PDA J Pharm Sci Technol; 1999; 53(3):111-4. PubMed ID: 10754699
    [No Abstract]   [Full Text] [Related]  

  • 4. Combating counterfeit drugs.
    Lancet; 2008 May; 371(9624):1551. PubMed ID: 18468523
    [No Abstract]   [Full Text] [Related]  

  • 5. Achieving "Zero" Defects for Visible Particles in Injectables.
    Johns J; Golfetto P; Bush T; Fantozzi G; Shabushnig J; Perry A; Degrazio F; Streich D; Miller J; Soukiassian H; Stanton A; Watson R
    PDA J Pharm Sci Technol; 2018; 72(6):640-650. PubMed ID: 30232141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
    Cash PW; Narwal R; Levitskaya SV; Krause S; Murphy D; Mazaheri M
    PDA J Pharm Sci Technol; 2016; 70(2):134-42. PubMed ID: 26797974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cleaning Validation: Complete Guide for Health - Based Approach in Chemical Cross - Contamination Risk Assessment.
    Tanyous JN
    PDA J Pharm Sci Technol; 2019; 73(2):204-210. PubMed ID: 30361288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report on the PQRI impurity characterization and quantification best practices survey.
    Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF
    Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396
    [No Abstract]   [Full Text] [Related]  

  • 9. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 10. Standardization of forensic drug analyses.
    Frank RS; Gunn JW
    J Forensic Sci; 1974 Jan; 19(1):163-7. PubMed ID: 4854386
    [No Abstract]   [Full Text] [Related]  

  • 11. Top ten hot topics in parenteral science and technology.
    Akers MJ; Nail SL; Saffell-Clemmer W
    PDA J Pharm Sci Technol; 2007; 61(5):337-61. PubMed ID: 18047174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 13. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.
    Carpenter JF; Randolph TW; Jiskoot W; Crommelin DJ; Middaugh CR; Winter G; Fan YX; Kirshner S; Verthelyi D; Kozlowski S; Clouse KA; Swann PG; Rosenberg A; Cherney B
    J Pharm Sci; 2009 Apr; 98(4):1201-5. PubMed ID: 18704929
    [No Abstract]   [Full Text] [Related]  

  • 14. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
    Giordani A; Kobel W; Gally HU
    Eur J Pharm Sci; 2011 May; 43(1-2):1-15. PubMed ID: 21420491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations.
    Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M
    PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing toxicology in RiskMAPP: setting ADEs based on the subsequent drug substance.
    Bercu JP; Sharnez R; Dolan DG
    Regul Toxicol Pharmacol; 2013 Feb; 65(1):157-61. PubMed ID: 22921793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future.
    Sargent EV; Flueckiger A; Barle EL; Luo W; Molnar LR; Sandhu R; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S3-S10. PubMed ID: 27230736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Validation of sterile pharmaceutical production. Considerations and experiences].
    Pongiluppi S
    Boll Chim Farm; 1985 Jul; 124(7):293-305. PubMed ID: 4074520
    [No Abstract]   [Full Text] [Related]  

  • 19. Counterfeiting and piracy of pharmaceuticals.
    Grackin A
    IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of poor-quality medicines in the 'developing' world.
    Newton PN; Green MD; Fernández FM
    Trends Pharmacol Sci; 2010 Mar; 31(3):99-101. PubMed ID: 20117849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.